These Analysts Boost Their Forecasts On Liquidia

On Friday, the U.S. Food and Drug Administration (FDA) approved Liquidia Corporation's LQDA Yutrepia (treprostinil) inhalation powder, a prostacyclin analog for adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to improve exercise ability.In August 2024, the FDA issued tentative approval of Yutrepia for the PAH and PH-ILD indications.Liquidia shares fell 5.2% to trade at $14.80 on Wednesday.These analysts made changes to their pri ...